×
How to Regulate Generative AI to Benefit the Healthcare Industry
Written by
Published on
Join our daily newsletter for breaking news, product launches and deals, research breakdowns, and other industry-leading AI coverage
Join Now

The rise of generative AI in medicine: Generative AI’s emergence in healthcare poses unique regulatory challenges for the Food and Drug Administration (FDA) and global regulators, requiring a novel approach distinct from traditional drug and device regulation.

  • The FDA’s usual process of reviewing new drugs and devices for safety and efficacy before market entry is not suitable for generative AI applications in healthcare.
  • Regulators need to conceptualize large language models (LLMs) as novel forms of intelligence, necessitating an approach more akin to how clinicians are regulated.
  • This new regulatory framework is crucial for maximizing the clinical benefits of generative AI while minimizing potential risks.

Current regulatory landscape: The traditional FDA approval process for drugs and devices serves two primary purposes that are not easily applicable to generative AI in healthcare.

  • It protects the public from unsafe and ineffective treatments and diagnostic tools.
  • It aids health professionals in deciding whether and how to incorporate new technologies into their practice.

Unique challenges of regulating generative AI: The nature of generative AI technology presents distinct regulatory hurdles that traditional approaches cannot adequately address.

  • Unlike static drugs or devices, generative AI systems are dynamic and continuously evolving, making point-in-time assessments less relevant.
  • The outputs of generative AI can vary widely depending on the input and context, making standardized safety and efficacy evaluations challenging.
  • The rapid pace of AI development outstrips the typically slower regulatory processes, potentially leading to outdated regulations by the time they’re implemented.

Proposed regulatory approach: To effectively regulate generative AI in healthcare, the FDA should consider adopting strategies similar to those used for overseeing medical professionals.

  • Implement a system of ongoing monitoring and evaluation, rather than a one-time approval process.
  • Develop guidelines for the ethical use of AI in clinical settings, similar to professional codes of conduct for healthcare providers.
  • Establish mechanisms for continuous learning and improvement, allowing AI systems to be updated and refined based on real-world performance and outcomes.

Potential benefits and risks: A well-designed regulatory framework for generative AI in healthcare could unlock significant benefits while mitigating potential dangers.

  • Benefits may include improved diagnostic accuracy, personalized treatment recommendations, and more efficient healthcare delivery.
  • Risks could involve AI-generated errors in diagnosis or treatment, privacy concerns related to patient data, and potential biases in AI algorithms.

Stakeholder collaboration: Effective regulation of generative AI in healthcare will require input and cooperation from various stakeholders.

  • Healthcare providers, AI developers, patient advocacy groups, and policymakers should be involved in shaping the regulatory approach.
  • International collaboration may be necessary to develop consistent global standards for AI in healthcare.

Looking ahead: Balancing innovation and safety: The regulation of generative AI in healthcare presents an opportunity to create a forward-thinking framework that fosters innovation while prioritizing patient safety.

  • Regulators must strike a delicate balance between enabling technological advancements and ensuring adequate safeguards are in place.
  • The evolving nature of AI technology will likely necessitate an adaptive regulatory approach that can keep pace with rapid developments in the field.
  • As generative AI becomes more prevalent in healthcare, ongoing research and evaluation will be crucial to understanding its long-term impacts and refining regulatory strategies accordingly.
How to Regulate Generative AI in Healthcare

Recent News

Baidu reports steepest revenue drop in 2 years amid slowdown

China's tech giant Baidu saw revenue drop 3% despite major AI investments, signaling broader challenges for the nation's technology sector amid economic headwinds.

How to manage risk in the age of AI

A conversation with Palo Alto Networks CEO about his approach to innovation as new technologies and risks emerge.

How to balance bold, responsible and successful AI deployment

Major companies are establishing AI governance structures and training programs while racing to deploy generative AI for competitive advantage.